According to the various clinical trials, HMG-CoA reductase inhibitors (statins) can effectively prevent the progression of atherosclerosis [56], so they are widely used in clinical practice as the first-line treatment strategy for primary prevention of atherosclerotic cardiovascular diseases [24,53,54]. This evidence concerns the gene HMGCR and atherosclerosis.